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Abstract 21 
 22 
Aim: We hypothesized that field asymmetric waveform ion mobility spectrometry (FAIMS) as a 23 
novel artificial olfactory technology could differentiate urine of women with malignant ovarian 24 
tumors from controls and women with benign tumors, based on previous findings on the ability of 25 
canine olfactory system to “smell” cancer. 26 
Patients and methods: Preoperative urine samples from 51 women with ovarian tumors, both benign 27 
and malignant, and from 18 women with genital prolapse, as controls, were collected. The samples 28 
were analyzed by FAIMS device. Data analysis was processed by quadratic data analysis (QDA) and 29 
linear discriminant analysis (LDA), and cross-validated using 10-fold cross-validation.  30 
Results: Thirty-three women had malignant ovarian tumors, of which 18 were high-grade cancers. 31 
FAIMS distinguished controls from malignancies with the accuracy of 81.3 % (sensitivity 91.2 % 32 
and specificity 63.1 %), and benign tumors from malignancies with the accuracy of 77.3 % 33 
(sensitivity 91.5 % and specificity 51.4 %). Moreover, low grade tumors were also separated from 34 
high grade cancers and benign ovarian tumors with accuracies of 88.7 % (sensitivity 87.8 % and 35 
specificity 89.6 %) and 83.9 % (sensitivity 73.1 % and specificity 92.9 %), respectively.  36 
Conclusions: This proof of concept-study indicates that the FAIMS from urine has potential to 37 
discriminate malignant ovarian tumors from no tumor-bearing controls and benign tumors.  38 
 39 
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Introduction 45 
Annually 22,000 new ovarian cancer (OC) cases are diagnosed in the United States, and the survival 46 
rates are poor due to the majority of OCs being detected at advanced stages [1]. While early diagnosis 47 
and adequate cytoreductive surgery improve prognosis, there is a need for better preoperative 48 
diagnostic methods for ovarian tumors.  49 
 50 
Various ultrasound-based models have been developed for preoperative evaluation of ovarian masses. 51 
These include e.g. Risk of Malignancy Index (RMI) [2] and logistic regression analyses and 52 
ultrasound-based rules from the International Ovarian Tumor Analysis (IOTA)-study. Although they 53 
have relatively high sensitivity and specificity, they are non-applicable for about 20 % of tumors [3]. 54 
 55 
Studies on urinary biomarkers for OC are relatively sparse. Urinary protein biomarkers, human 56 
epididymis protein 4 (HE4) and mesothelin, have shown to improve the early detection of serous OC 57 
compared to serum biomarkers [4]. Metabolite changes related to OC have been discovered as 58 
potential biomarkers [5,6], like N1,N12-diacetylspermine in polyamine analyses [7]. In addition, 59 
circulating microRNAs have been shown to be abundant in urine of OC patients [8]. 60 
 61 
Many diseases are linked to distinct odors caused by volatile organic compounds (VOCs) released 62 
into exhaled air, urine, blood and stool [9]. Horvath et al. trained dogs to discriminate OC patients 63 
and healthy controls from tissue samples [10] and blood samples from cancer patients [11] with high 64 
accuracy. The costly training, limited working capacity and cultural factors have prevented the use 65 
of “sniffer dogs” in the clinic. Artificial olfaction with electronic devices could be easier to validate 66 
and adopt into clinical practice [9].  67 
   68 
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Gas chromatography-mass spectrometry (GC-MS) has been used extensively in analysis of VOCs 69 
but it involves complex technology and has high costs. Electronic nose (eNose) technology provides 70 
a more economical and simpler way to qualitatively analyze VOCs. The technology mimics the 71 
working principle of mammalian olfactory system (Figure 1). Ion mobility spectrometry (IMS) works 72 
according to the same principles, providing a qualitative VOC spectrum from the sample. Field 73 
asymmetric waveform IMS (FAIMS) is a modern and sensitive variant of IMS providing a high 74 
sensitivity and stability [12]. The working principle of FAIMS is illustrated in Figure 2. 75 
   76 
There is mounting evidence of the potential of eNose devices in detection of cancer from various 77 
sample media [12]. FAIMS specifically has previously been shown to detect colorectal and pancreatic 78 
cancers from urine [13,14]. Detection of OC has been only attempted from cancer tissue [15]. Urine 79 
is a promising sampling method since it can be obtained non-invasively.  80 
  81 
We hypothesized that FAIMS would be capable of differentiating the urine of women with OC from 82 
benign ovarian tumors and controls.  83 
  84 
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Materials and methods  85 
Subjects and study design 86 
Between May 2013 and March 2016, 60 women with an adnexal tumor scheduled for surgery gave a 87 
morning urine sample in the operation day at the Department of Obstetrics and Gynecology of 88 
Tampere University Hospital. They were all postmenopausal, and none of them had an ongoing 89 
treatment for cancer. After operation nine tumors were excluded due to their non-ovarian origin or a 90 
concurrent malignant tumor. The final sample size after exclusions was 51. Eighteen women 91 
scheduled for urinary incontinence or genital prolapse surgery were recruited as controls. The samples 92 
were stored at -70°C until analysis. Because of the proof-of-concept nature of the study, no power 93 
calculations could be done. The size of the study population was based on the experience from 94 
previous studies with similar technology [16]. 95 
 96 
The samples were defrosted and analyzed using Owlstone Lonestar (Owlstone Inc, Cambridge, 97 
United Kingdom) device which uses FAIMS technique. The sensor was coupled with ATLAS 98 
sampling unit (Owlstone Inc, Cambridge, United Kingdom) that standardizes the analytical 99 
conditions by controlling the temperature and dilution of the VOCs evaporated from the sample. 100 
 101 
Protocol of FAIMS 102 
For FAIMS analysis, we used settings previously described by Arasaradnam et al [13]. The step-by-103 
step analysis protocol was as follows:  104 
1) Urine samples were first thawed at room temperature and analyzed in random order. 105 
2)  A 5 ml urine sample was aliquoted to a 30 ml glass vial and warmed to 40°C.  106 
3) Once the sample achieved the target temperature, three consecutive scans were conducted to 107 
minimize the effect of scan-to-scan variation. 108 
6 
 
4) After the analysis, the sample vial was removed from the sampling unit and a vial of 5 ml of 109 
purified water was placed in to the chamber. 110 
5) The vapour released from the purified water acts as a cleaning agent that removes the carry-over 111 
effect of trace VOCs from the urine sample that are retained in the sensor. Five consecutive scans 112 
with purified water were conducted.  113 
The next urine sample was placed to the sampling chamber and the process was repeated. To ensure 114 
stable and clean carrier gas for the system, we utilized standard pressurized clean air that was cleaned 115 
from residual humidity with a silica gel filter and from residual VOCs with activated charcoal filter 116 
before entering the system. We used the flow settings recommended by the manufacturer for urine 117 
samples: The flow rate over the sample was 500 ml/min, which was mixed to 2000 ml/min stream of 118 
clean air for a total flow of 2500 ml/min for the sensor. The FAIMS scanning settings used were also 119 
ones provided by the manufacturer: Dispersion field from 0 to 90 % was scanned in 51 steps and 120 
compensation voltage from -6 to +6 V was scanned in 512 steps. Each scan contains two ion windows, 121 
one for negative and one for positive ions. One window is produced by the negative ions that collide 122 
the positive detector and the other is produced by the positive ions that collide the negative detector, 123 
respectively. The detectors are illustrated in Figure 2.  124 
The ion window is a spectrum that has compensation voltage on the X axis and dispersion field on 125 
the Y axis as seen in Figure 3. The compensation voltage is the base voltage between the electric 126 
plates in the separation part of the FAIMS sensor. This biases the ion flow either towards negative or 127 
positive plate. The dispersion field strength represents the strength of the electrical field between the 128 
plates as a percentage of the maximum field that can be created by the system. The ion window is 129 
compiled by adjusting the dispersion field strength stepwise and on each step scanning the selected 130 
compensation voltage range at each step. The scans were saved on the hard drive of the Lonestar 131 
system from which they were transferred to an USB drive for statistical analysis. 132 
 133 
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Statistical methods  134 
The last of the three scans from the urine sample was found to be equal in performance when 135 
compared to the average of three scans, and was taken for analysis. One scan consists of a matrix of 136 
52,200 measurement values, including both positive and negative ion window. The areas with no 137 
response were removed and the remaining signal was downsampled, selecting every other line and 138 
column of the scan, leaving 1,536 points for each measurement.  139 
 140 
Forward feature selection with linear discriminant analysis (LDA) and quadratic discriminant 141 
analysis (QDA) were utilized to find discriminating features from each group. Both LDA and QDA 142 
seek a classifier that is optimal for discrimination of the groups. LDA is a special case of QDA where 143 
the covariance of each group is assumed to be equal which results in a linear discriminator whereas 144 
QDA allows the covariances to differ which also enables quadratic, parable-shaped discriminators. 145 
Because LDA is a simpler method, it is preferred as the first option to test. The results were cross-146 
validated by 10-fold cross-validation to avoid overfitting. In this method, the dataset is divided into 147 
10 groups. One group is then excluded from the dataset and the remaining nine groups are used to 148 
create the classification parameters as the training set. The excluded group is then classified using 149 
these parameters. Since, due to random division for the cross validation, the classification parameters 150 
change to a certain extend in every run, the process was repeated 100 times to reduce the effect of 151 
variation and to calculate averages and standard deviations for classification results. The analysis was 152 
conducted with MATLAB R2017b (MathWorks Inc, Natick, MA, USA). 153 
 154 
Results  155 
Characteristics of the final study population are presented in Table 1. The averages and standard 156 
deviations of the 100 runs of QDA and LDA analysis are given in Table 2. The performances of QDA 157 
and LDA seem to be mostly equal yet there is a notable difference in comparisons of benign tumors 158 
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with low grade vs. high grade malignant tumors, respectively. The data produced by FAIMS is 159 
nonlinear by nature [17], and it is likely that nonlinear methods such as QDA yield better results in 160 
most cases, especially when the differences between groups are less distinct. By QDA analysis, 161 
benign ovarian tumors were distinguished from malignant tumors with sensitivity and specificity of 162 
91.5 % and 51.4 %, respectively. However, the specificity improved to 79.7 % when they were 163 
compared only to high-grade ovarian cancers. Even low grade ovarian malignancies were 164 
discriminated from high grade ovarian cancers with sensitivity of 87.8 % and specificity of 89.6 %, 165 
and from benign ovarian tumors with sensitivity of 73.1 % and specificity of 92.9 %, respectively.  166 
Figure 3 shows average FAIMS outputs from urine sample of a control and of a woman with ovarian 167 
cancer. 168 
 169 
Discussion 170 
This study provides preliminary evidence that FAIMS analysis of VOCs can discriminate urine 171 
samples from OC patients, patients with non-malignant tumors and healthy controls. High grade 172 
ovarian cancers seem to be separated from low grade ovarian cancers, benign ovarian tumors and 173 
controls.  174 
 175 
The study further demonstrates that OC is associated with distinct odor [18-20]. The fact that this 176 
phenomenon is apparent in urine suggests that a systemic process is involved. It is apparent that 177 
metastatic, systemic cancer may elicit profound changes in urine composition that may be an 178 
indication of decreasing renal function. However, in the case of colorectal cancer, even early stage 179 
cancers could be detected [13]. There is in fact mounting body of evidence that cancer releases VOCs 180 
to systemic circulation that consequently are released through alveoli to breath and via glomerular 181 
filtration to urine [21]. This suggests that breath and urine can be considered alternative sampling 182 
methods for same VOCs. The feasibility of FAIMS/IMS has been demonstrated in both sampling 183 
9 
 
sources [13,22]. Reliable sampling from exhaled breath is challenging [23] and the performance of 184 
breath VOC analysis in OC seems to be inferior to our results obtained from urine [18,24]. Since 185 
urine can be obtained non-invasively, we consider it as a more promising sampling source for VOC 186 
analysis in OC.  187 
 188 
VOCs in different sample mediums and cancers seem to have common features, which are related to 189 
oxidation such as benzene derivates [13,18,21]. The metabolic origin and function of most of these 190 
VOCs are unclear. They can originate from endogenous and exogenous sources and may thus be a 191 
result also from environmental exposure instead of the cancer [21]. In this study we achieved a good 192 
discrimination of high grade and low grade cancers. It has been suggested that KRAS and TP3 193 
mutations play a role as a watershed in development of high or low grade serous OC, i.e. type I and 194 
II OCs [25]. These single mutations have resulted in VOC changes in cellular model [26] that reflect 195 
those found in urine in other cancers [13]. We speculate that the VOC alterations concerning various 196 
mutations should be studied in future also in ovarian cancer. 197 
 198 
This study must be considered as preliminary, and the results should be verified in larger patient 199 
cohorts with this repeatable method. However, there is urgent need for early detection of especially 200 
aggressive type II OCs, with an ultimate goal to improve the prognosis of this devastating disease 201 
[25]. An important topic in future FAIMS research is to examine if cytoreductive surgery and 202 
immunosuppressive therapy have influences on VOC emissions of urine samples. FAIMS technology 203 
itself has advantages compared to GC-MS- and eNose implications; the technology by nature is 204 
sensitive to trace concentrations of molecules, is considerably more economical than MS-based 205 
methods, and does not suffer stability problems of other eNose technologies [27]. In contrast to canine 206 
studies, FAIMS is standardized and repeatable, whereas it is almost impossible to replicate research 207 
settings of canine studies because of variation in dogs. 208 
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 209 
Our study has also limitations. First, the present results cannot as such be generalized to unselected 210 
populations, but rather should be considered valid in the setting of tertiary hospitals, as part of the 211 
diagnostic work-up of adnexal tumors. Second, the number of analyzed urine samples was quite 212 
small. However, the proportions of three patient groups (controls, benign and malignant tumors) were 213 
balanced. Third, the considerable number of low malignant potential and borderline ovarian tumors 214 
in our study certainly has an influence on our results comparing benign and malignant ovarian tumors, 215 
and may have contributed to the rather great deviation seen between comparisons of benign tumors 216 
and all or low-grade malignant tumors. However, the comparisons between benign ovarian tumors or 217 
controls and high grade ovarian tumors are more accurate and specific. Fourth, the storage time of 218 
our samples was several years, which may have reduced the VOC emissions and thus differences 219 
between groups, as has been shown in a recent study examining the effect of storage on VOC profiles 220 
of urine [28]. In addition, the effects of the diet and possible medications may have had influence on 221 
the concentration and composition of urine although the samples were collected in the morning after 222 
at least four hours fasting. The fact that the highest discrimination rate was achieved for benign tumors 223 
and controls suggests that there is a degree of bias between patient groups. This may also result from 224 
the larger and more heterogenous nature of cancer group.  225 
 226 
Conclusion 227 
According to our results, we propose that the VOC signature of urine of ovarian cancer patients can 228 
be recognized by FAIMS and that it has potential for being a non-invasive method in the detection of 229 
ovarian malignancy. Our novel study encourages us to examine further possibilities of FAIMS for 230 
diagnostics and follow-up of gynecological malignancies.  231 
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Table 1. Demographic data of study population 325 
 Malignant tumors 
 
Benign tumors Controls 
n 33 
 
18 18 
Age (years) 
Median 
(range) 
 
64  
(51-82) 
 
 
64 
(51-73) 
 
71  
(55-83) 
Diagnosis (n) Low grade cancers (15) 
- mucinous adenocarcinoma 
Stage IA and IC (1+1) 
- endometrioid 
adenocarcinoma Stage IA 
(1) 
- mucinous borderline Stage 
IA (5) 
- serous borderline Stage IA 
(4) 
- Sertoli-Leydig cell tumor 
Stage IIIC (1) 
- Granulosa cell tumor 
Stage IA (2) 
 
High grade cancers (18) 
 
- carcinosarcoma  
Stage IIIC (1) 
- high grade serous 
adenocarcinoma 
• Stage IC (1) 
• Stage IIC (1) 
• Stage III/IV (15) 
 
Serous cystadenoma (9) 
Mucinous cystadenoma 
(1) 
Fibroma (2) 
Simple cyst (3) 
Endometriotic cyst (2) 
Necrotized cyst (1) 
Genital prolapse or 
urinary incontinence (18) 
 326 
Table 2. Results of FAIMS signal data and QDA and LDA classification 327 
 328 
 329 
 330 
 331 
 332 
 333 
 334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
Classification 
pairs 
 QDA   LDA  
Accuracy 
(%) 
(±2 Std) 
Sensitivity 
(%)  
(±2 Std) 
Specificity 
(%) 
(±2 Std) 
Accuracy 
(%) 
(±2 Std) 
Sensitivity 
(%) 
(±2 Std) 
Specificity 
(%)  
(±2 Std) 
Benign ovarian 
tumors vs. controls 
 
Controls vs. 
malignant ovarian 
tumors   
 
Controls vs. high 
grade ovarian 
cancers 
91.9 
(±9.8) 
 
81.3 
(±8.2) 
 
 
81.9 
(±5.2) 
93.4 
(±11.4) 
 
91.2 
(±7.2) 
 
 
89.1 
(±2.8) 
90.4 
(±14.4) 
 
63.1 
(±16.0) 
 
 
74.6 
(±9.6) 
86.1 
(±9.6) 
 
81.2 
(±5.8) 
 
 
82.1 
(±6.0) 
86.0 
(±11.2) 
 
90.4 
(±5.2) 
 
 
88.7 
(±3.2) 
86.1 
(±12.2) 
 
64.3 
(±12.8) 
 
 
75.6 
(±11.8) 
 
Benign vs. 
malignant ovarian 
tumors 
 
77.3 
(±13.8) 
 
91.5 
(±6.4) 
 
51.4 
(±32.0) 
 
65.9 
(±13.8) 
 
87.1 
(±9.0) 
 
27.1 
(±38.6) 
 
Benign ovarian 
tumors vs. low 
grade ovarian 
cancers 
 
Benign ovarian 
tumors vs. high 
grade ovarian 
cancers 
 
83.9 
(±23.4) 
 
 
 
82.5 
(±10.0) 
 
73.1 
(±41.4) 
 
 
 
85.3 
(±15.0) 
 
92.9 
(±11.4) 
 
 
 
79.7 
(±12.0) 
 
59.3 
(±7.0) 
 
 
 
82.5  
(±9.6) 
 
35.9 
(±14.0) 
 
 
 
85.0 
(±15.0) 
 
78.8 
(±5.8) 
 
 
 
79.9 
(±11.2) 
 
Low grade vs. high 
grade ovarian 
cancers 
 
88.7 
(±11.2) 
 
87.8 
(±12.8) 
 
 
89.6 
(±16.6) 
 
82.0 
(±10.8) 
 
84.3 
(±16.0)    
 
79.7 
(±13.4) 
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Figure 1. The working principle of mammary and eNose compared 342 
A) VOCs enter a sampling unit where the humidity, the temperature and the concentration of the 343 
sample are optimized. 344 
B) Optimized sample enters the sensor unit where different VOCs attach to different areas of the 345 
sensor and produce electrical currents. 346 
C) Electrical currents are referred to a computing system for analysis where they are associated with 347 
previously gathered information. 348 
D) A result of the analysis is produced. 349 
 350 
 351 
 352 
 353 
 354 
 355 
 356 
 357 
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Figure 2. Illustration on the working principle of FAIMS  358 
A) Sample vial is placed in to the sampling chamber where VOCs are released from the sample. 359 
VOCs are then transferred to the analyzer by clean air flow.  360 
B) In the analyzer, VOCs are first ionized by a radioactive isotope and gain electrical charge. 361 
C) Ionized VOCs enter separation area where they are alternately exposed to high and low electric 362 
fields between the electric plates. The plates also have a baseline compensation voltage that is 363 
periodically adjusted. The different properties of VOCs cause them to travel at different speed in the 364 
separation chamber and behave differently in high and low electric fields. This results in separation 365 
of the VOCs according to their charge, shape and mass.  366 
D) At the last stage of the analysis, VOCs collide with detectors, creating electric currents that create 367 
a unique spectrum for each molecular mixture. 368 
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Figure 3. Average FAIMS spectrum from a patient with ovarian cancer and from a control 376 
Stars indicate the areas of the spectrum that yielded optimum discrimination of the two groups. 377 
Compensation voltage is on X-axis and dispersion field strength is on Y-axis.  378 
 379 
